UK's ValiRx half-year loss narrows, cash position improves
UK's ValiRx half-year loss narrows, cash position improves
Overview
UK cancer therapeutics developer's half-year loss narrowed, administrative expenses reduced
Company's cash position improved after June fundraising
No dividend proposed for the period
Outlook
Company says it will require additional funding within the next 12 months
Company continues to pursue non-dilutive grants and asset-level financing for subsidiaries
ValiRx notes ongoing commercial interest in its patient-derived cell models despite challenging macro environment
Result Drivers
LEAN STRATEGY - Co said full implementation of revised lean strategy led to further reduction in administrative expenses
FUNDRAISING - Co said June fundraising strengthened financial position and improved cash balance
STRICTER DUE DILIGENCE - Co said stricter asset selection and due diligence approach enabled focus on projects that can be expedited through development
Company press release: ID:nRSO7058Ua
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Loss per share from continuing operations |
| 0.09p |
|
Reuters Recommended Reads
Sept 14 - British man admits drugging and raping wife over more than two decades
Sept 14 - Definium's LSD-based anxiety, depression drug scores another trial win
Sept 14 - Electra Therapeutics targets $977.6 million valuation in US IPO
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)